北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科  > 期刊论文
学科主题: 泌尿外科学
题名:
新型抗胆碱能药物托特罗定治疗膀胱过度活动症的临床研究
其他题名: Tolterodine,a new antimuscarinic agent,in patients with overactive bladder
作者: 吴士良1; 杨勇1; 薛兆英1; 那彦群1; 宋波1; 金锡御1; 丁强1; 张元芳1; 郭应禄1
关键词: 膀胱过度活动症 ; 托特罗定 ; 奥昔布宁
刊名: 中华泌尿外科杂志
发表日期: 2001
DOI: 10.3760/j:issn:1000-6702.2001.04.008
卷: 22, 期:4, 页:217-219
收录类别: 中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型: Journal Article
摘要: 目的 评价新型抗胆碱药物托特罗定治疗膀胱过度活动症的有效性和安全性。 方法 采用随机、双盲、双模拟、平行对照的方法对207例膀胱过度活动症患者进行托特罗定与奥昔布宁的对比研究,服药方法每日2次,每次托特罗定2mg或奥昔布宁5mg。 结果 治疗6周后,托特罗定组(103例)24h平均排尿次数减少(3.0±3.4)次,其中尿失禁患者的平均尿失禁次数减少(1.5±1.8)次;奥昔布宁组(104例)治疗后24h平均排尿次数减少(4.6±6.4)次,平均尿失禁次数减少(2.4±2.1)次,两组间差别无显著性意义(P>0.05)。托特罗定组患者副作用发生率66.9%,其中口干为55.3%;而奥昔布宁组发生率为87.5%,口干为76.9%,两组间差别有显著性意义(P<0.05)。 结论 托特罗定是治疗膀胱过度活动症的有效药物,疗效与奥昔布宁相同,但不良反应明显低于奥昔布宁。 Objective To evaluate the efficacy and tolerability oftolterodine in patients with an overactive bladder. Methods A randomized,double-blind,double-simulant,parallel-controlled,multicentric study was carried out in 207 patients with bladder overactivity,patients received either tolterodine (2 mg twice daily)or oxybutynin (5 mg twice daily). Results After 8 weeks of treatment,the mean frequency of micturition decreased 3.0±3.4 times and 4.6±6.4 times in those receiving tolterodine (n=103) and oxybutynin(n=104),respectively.Among those with urge incontinence,the mean number of incontinence episodes decreased 1.5±1.8 times and 2.4±2.1 times,respectively,in those receiving tolterodine and oxybutynin.The effect of tolterodine and oxybutynin on these two micturition variables was statistically equivalent.In the tolterodine group,the total incidence of adverse event was 66.9% and the incidence of dry mouth,the most common adverse,was 55.3%.While in the oxybutynin group,the incidences were 87.5% and 76.9% respectively.The incidences of adverse events and dryness were significantly lower in those on tolterodine than in those on oxybutynin. Conclusions Tolterodine 2 mg twice daily had the equivalent efficacy on patients with overactive bladder as compared to oxybutynin 5 mg twice daily,and the adverse events of tolterodine were lower than oxybutynin.
语种: 中文
原文出处: 查看原文
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/45459
Appears in Collections:北京大学第一临床医学院_泌尿外科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.100034 北京大学第一医院,北京大学泌尿外科研究所
2.重庆第三军医大学西南医院
3.上海华山医院

Recommended Citation:
吴士良,杨勇,薛兆英,等. 新型抗胆碱能药物托特罗定治疗膀胱过度活动症的临床研究[J]. 中华泌尿外科杂志,2001,22(4):217-219.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[吴士良]'s Articles
[杨勇]'s Articles
[薛兆英]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[吴士良]‘s Articles
[杨勇]‘s Articles
[薛兆英]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace